NCT07212946CompletedPhase 2
Ayahuasca and Esketamine for Major Depression
Four Doses of Ayahuasca or Esketamine in Major Depressive Disorder: a Double-blind Randomized Trial
Source: ClinicalTrials.gov · Last updated 29 Dec 2025
Brief summary (registry, in English)
Double-blind, randomized trial comparing 4 weekly doses of oral ayahuasca and esketamine in patients with major depression.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 22 (actual)
- First submitted
- 1 Oct 2025
- Start date
- 30 Oct 2022
- Primary completion date
- 30 Oct 2024
- Lead sponsor
- University of Sao Paulo
- Diseases
- Depression
- NCT number
- NCT07212946
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 22
- From 30 Oct 2022 to the primary completion date, 30 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Presence of psychiatric and other medical comorbidities
Who the study is looking for
- \- Clinical diagnosis of depressive disorder
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital das Clinicas da FMRP USP Coordinator of this site? Confirm its status | Ribeirão Preto | Brazil | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.